SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-24-047138
Filing Date
2024-02-27
Accepted
2024-02-27 08:32:23
Documents
7
Effectiveness Date
2024-02-27

Document Format Files

Seq Description Document Type Size
1 S-8 d775790ds8.htm S-8 48982
2 EX-5.1 d775790dex51.htm EX-5.1 8227
3 EX-23.2 d775790dex232.htm EX-23.2 2540
4 EX-99.3 d775790dex993.htm EX-99.3 60260
5 EX-FILING FEES d775790dexfilingfees.htm EX-FILING FEES 14545
6 GRAPHIC g775790g0224055654160.jpg GRAPHIC 1649
7 GRAPHIC g775790g0224060118607.jpg GRAPHIC 5840
  Complete submission text file 0001193125-24-047138.txt   146255
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-277385 | Film No.: 24682181
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)